Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | NA |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | head and neck squamous cell carcinoma |
| ICD-0-3 | C76.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | HNSCC tissues, CAL-27 and SCC-9 cell lines,HN4, HN6 and HN30 cell lines,Normal oral epithelial cells (Normal) |
| Expression Pattern | up-regulated |
| Function Description | ANRIL expression was upregulated in HNSCC and correlated with tumor progression. Further functional analysis showed that knockdown of ANRIL significantly inhibited proliferation in vivo and in vitro. ANRIL functioned as a ceRNA (competing endogenous RNAs) for miR-125a-3p and upregulated FGFR1 (fibroblast growth factor receptor-1), which could promote tumor growth. Moreover, we confirmed that ANRIL promoted HNSCC activity via FGFR1 with a FGFR1 inhibitor in vivo and in vitro. Thus, it could be concluded that ANRIL promoted the progression of HNSCC via miR-125a-3p/FGFR1/MAPK signaling, which might provide a new target for the diagnosis and treatment of HNSCC. |
| Pubmed ID | 30555745 |
| Year | 2018 |
| Title | Long non-coding RNA ANRIL promotes tumorgenesis through regulation of FGFR1 expression by sponging miR-125a-3p in head and neck squamous cell carcinoma |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for head and neck squamous cell carcinoma | OMIM COSMIC |